Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naive patients with chronic hepatitis B
- Authors
- Seo, Hee Yeon; Lee, Han Ah; Ko, Soon Young; Wang, Joon Ho; Kim, Jeong Han; Choe, Won Hyeok; Kwon, So Young
- Issue Date
- Jun-2017
- Publisher
- KOREAN ASSOC STUDY LIVER
- Keywords
- Tenofovir; Chronic hepatitis B
- Citation
- CLINICAL AND MOLECULAR HEPATOLOGY, v.23, no.2, pp 154 - 159
- Pages
- 6
- Indexed
- SCOPUS
ESCI
KCI
- Journal Title
- CLINICAL AND MOLECULAR HEPATOLOGY
- Volume
- 23
- Number
- 2
- Start Page
- 154
- End Page
- 159
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/29401
- DOI
- 10.3350/cmh.2016.0067
- ISSN
- 2287-2728
2287-285X
- Abstract
- Background/Aims: Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was to investigate the incidence and outcome of early alanine aminotransferase (ALT) flare in treatment-naive patients with CHB during long-term TDF monotherapy. Methods: One hundred eighty-one treatment-naive CHB patients were treated with a 300-mg once-daily dose of TDF for more than 12 weeks. Virological markers of hepatitis B virus (HBV) and biochemical data were measured at baseline and every 4-12 weeks during the therapy. The proportion of patients with undetectable HBV DNA level (<100 copies/mL) was noted. Results: The median age was 48.3 years and 122 patients (67.4%) were men. Hepatitis B envelope antigen (HBeAg) was positive in 101 patients (55.8%). No patient had cirrhosis. The median follow-up duration was 45 weeks (12-155 weeks). ALT flare (>5 x upper limit of the normal range) occurred in seven patients (3%) without viral breakthrough within the first 8 weeks after the start of TDF monotherapy. Among them, six patients were HBeAg-positive and one patient was HBeAg-negative. All cases of early ALT flares resolved within 4 weeks and virologic response was observed in all patients without interruption or discontinuation of treatment. Conclusions: Continuous TDF monotherapy was effective and safe in treatment-naive patients with CHB who experienced early ALT flares followed by a decrease in HBV DNA level.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.